AJMC: Your findings suggest that roughly 1 in 10 Medicare Advantage enrollees may face forced disenrollment in 2026. From a ...

After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...

As employers grapple with the soaring demand for glucagon-like peptide-1 (GLP-1) medications, Eric Levin, CEO and cofounder ...

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...

Rural cardiovascular disparities and limited specialist access are motivating AI decision-support adoption to help determine ...

Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks ...

Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...

Patients taking ACE inhibitors and ARBs saw a 16% reduction in their risk of cancer progression (HR, 0.84; 95% CI, 0.71-0.99; ...

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the ...

ACOs entering MSSP with higher spending were consistently more likely to earn bonuses—a gap that persisted after a 2017 ...

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to ...

Emerging CRC diagnostic tools along with better public awareness could help reverse rising deaths in younger adults, says Jordan Karlitz, MD.